Merck & Co. announced it is acquiring Schering-Plough in a $41.1 billion deal that would grant Merck access to Schering-Plough's robust biotech, consumer-health and animal-health businesses. Merck CEO Richard Clark called the merger a "transformational event" that would put his company "at the forefront of drug discovery for years to come."

Related Summaries